Phase 1RecruitingPriority 4 · Lower priorityNCT05010005
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Plain-language summary
This trial is testing duvelisib (an oral PI3K inhibitor) for patients with extranodal NK/T-cell lymphoma or T-cell prolymphocytic leukemia whose disease has come back or stopped responding to prior treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. This trial is available at 9 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Ruxolitinib (DRUG): Ruxolitinib 20mg BID | Duvelisib (DRUG): Duvelisib 25mg, 50mg, or 75mg BID
Ruxolitinib, Duvelisib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details